



Pfizer Inc.

275 North Field Drive

Lake Forest, IL 60045

August 24, 2026

Update on the Impact of the ZHOPL Facility Flooding

Dear Customer,

In late July and early August, heavy monsoon rains severely flooded the Zydus Hospira Oncology Private Limited (ZHOPL) manufacturing facility in Gujarat, India. ZHOPL is a 50:50 joint venture between Pfizer and Zydus Lifesciences Limited that produces sterile injectable generic oncology medications for Pfizer Global Hospital & Biosimilars. All colleagues working at the plant are safe and accounted for. **The overall impact to Pfizer and our U.S. Hospital & Biosimilars business is expected to be limited; the effects may be more concentrated on certain products within our generic sterile injectable oncology portfolio.**

We understand our oncology customers may have questions and concerns about the potential impact to supply and continuity of patient care. We are committed to providing timely and transparent supply updates to our U.S. customers and—consistent with our crisis management plans—are sharing the following preliminary updates now, with the knowledge that further facility assessments and details are required before additional specifics can be shared more broadly.

Please note the following information regarding production impact:

- The site remains closed while the flood damage is assessed. Recovery efforts are safely underway, and power restoration is in progress.
- We are currently assessing the production restart timeline. An estimated date is not yet available, and customers will be updated as more information becomes available.
- Alternative sites within our global network and third-party manufacturing options are being evaluated.

Please note the following information regarding potential supply disruptions:

- Out of an abundance of caution, while facility recovery assessments are underway, **we have proactively placed the impacted generic sterile injectables oncology portfolio on allocation to support equitable patient access and help prioritize availability for critical products most needed by patients.**
- We recognize the critical nature of our generic sterile injectable oncology portfolio and are committed to supporting supply availability for this vulnerable patient population.
- Product allocations vary between 100% of historical demand or partial allocation and are currently based on historical demand, currently available inventory within the distribution chain, and anticipated supply recovery dates.
- As we learn more from the site assessment and estimated production restart dates, we will make the necessary allocation adjustments and provide timely updates to help customers plan for patient care.
- Please note that Pfizer does not produce Biosimilars oncology products at this facility.

The U.S. Food and Drug Administration (FDA) has been informed of the situation, and we will continue to keep the FDA and other regulatory bodies informed as additional details become available. Product supply availability is subject to change as the situation evolves. Please refer to our [Availability Report](#), updated weekly and accessible on the PfizerHospitalUS.com homepage, for the latest information.

For additional product availability questions, please reach out to your Pfizer Hospital Sales Representative or Account Director. Alternatively, the Supply Continuity Team can be contacted between 7am and 5pm CT at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]). For medical questions regarding these products, please contact Pfizer Medical Information at 1-800-438-1985 [Option 3] Monday to Friday between 9am and 5pm ET or visit www.pfizermedical.com.

We appreciate Zydus' collaboration, the support of local teams, and our customers' concern for colleagues at ZHOPL. As recovery continues, we remain focused on minimizing disruption to patient care and supporting our colleagues, their families, and the Gujarat community.

We appreciate your patience and partnership during this time.

Thank you,

Adam Van Eperen

U.S. Hospital Portfolio Lead

Pfizer Global Hospital & Biosimilars, U.S. Commercial

Appendix:**Pfizer Global Hospital & Biosimilars Products Currently on Allocation Until Further Notice****(as of 8/7/26)**

NDC	Product Description
61703-0332-18	Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0323-22	Bleomycin for Injection, USP 30 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0305-38	Cytarabine Injection 100 mg/5 mL (20 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0303-46	Cytarabine Injection 1,000 mg/50 mL (20 mg/mL) Pharmacy Bulk Package Glass Vial
61703-0304-36	Cytarabine Injection 500 mg/25 mL (20 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0319-22	Cytarabine Injection 2 g/20 mL (100 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00409-0368-01	Docetaxel injection, USP 160 mg/8 mL (20 mg/mL) Multiple Dose Glass Vial
00409-0367-01	Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) Multiple Dose Onco-Tain™ Glass Fliptop Vial
00409-0201-10	Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial
00409-0201-20	Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial
00409-0366-01	Docetaxel Injection, USP 20 mg/mL (20 mg/mL) Single Dose Onco-Tain™ Glass Fliptop Vial
00409-0201-02	Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00069-1542-20	DOXOrubicin Hydrochloride Injection, USP 200 mg/100 mL (2 mg/mL) Multiple Dose Onco-Tain® Glass Fliptop Vial
00069-0358-20	DOXOrubicin Hydrochloride Injection, USP 10 mg/5 mL (2 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial
00069-0343-02	DOXOrubicin Hydrochloride Injection, USP 50 mg/25 mL (2 mg/mL) Single Dose ONCO-TAIN® Vial
00069-0277-02	DOXOrubicin Hydrochloride Injection, USP 20 mg/10 mL (2 mg/mL) Single Dose ONCO-TAIN® Glass Fliptop Vial
00009-5093-10	Ellence® (epirubicin hydrochloride injection) 200 mg/ 100 mL) Onco-Tain™ Single Dose Glass Fliptop Vial
00009-5091-25	Ellence® (epirubicin hydrochloride injection) 50 mg/ 25 mL (2 mg/mL) Onco-Tain™ Single Dose Glass Fliptop Vial
100409-0185-01	Gemcitabine for Injection, USP 200 mg Single Dose Glass Fliptop Vial

00409-0186-01	Gemcitabine for Injection, USP 1 g Single Dose Glass Fliptop Vial
00409-0187-01	Gemcitabine for Injection, USP 2 g ONCO-TAIN™ Single Dose Glass Fliptop Vial
00409-0183-01	Gemcitabine Injection 200 mg/5.26 mL (38 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00409-0182-01	Gemcitabine Injection 2 g/52.6 mL (38 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00409-0181-01	Gemcitabine Injection 1 g/26.3 mL (38 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00013-2576-05	Idamycin PFS® (idarubicin hydrochloride injection) 5 mg/5 mL (1 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial
00013-2596-20	Idamycin PFS® (idarubicin hydrochloride injection) 20 mg/20 mL (1 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial
00013-2586-10	Idamycin PFS® (idarubicin hydrochloride injection) 10 mg/10 mL (1 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial
00009-7529-10	Camptosar® (Irinotecan Hydrochloride Injection, USP) 40 mg/2 mL (20 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial
61703-0349-16	Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0349-09	Irinotecan Hydrochloride Injection, USP, 100 mg/5 mL (20 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00009-0112-05	Camptosar® (Irinotecan Hydrochloride Injection, USP) 100 mg/5 mL (20 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial
61703-0349-36	Irinotecan Hydrochloride Injection, USP, 500 mg/25 mL (20 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00009-0082-02	Camptosar® (Irinotecan Hydrochloride Injection, USP) 300 mg/15 mL (20 mg/mL) Onco-Tain® Single Dose Glass Fliptop Vial
61703-0343-66	Mitoxantrone Injection, USP 30 mg/15 mL (2 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0343-65	Mitoxantrone Injection, USP 25 mg/12.5 mL (2 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0343-18	Mitoxantrone Injection, USP 20 mg/10 mL (2 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial
00409-0801-01	Nipent™ (pentostatin for injection) 10 mg Single Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0363-18	Oxaliplatin Injection 50 mg/10 mL (5 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
61703-0363-22	Oxaliplatin Injection 100 mg/20 mL (5 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
00409-2188-01	Pemetrexed Injection 500 mg/20 mL (25 mg/mL) Single Dose Vial
00409-3532-01	Pemetrexed Injection 1 g/40 mL (25 mg/mL) Single Dose Vial
00409-1045-01	Pemetrexed Injection 100 mg/4 mL (25 mg/mL) Single Dose Vial

0409-0302-01	Topotecan Injection 4 mg/4 mL (1 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial
--------------	--



© 2026 Pfizer Inc. All rights reserved. August 2026